Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

Cited by (114)

Items 101–114 of 114

1. Targeting BCL2 with Venetoclax Enhances the Efficacy of the <i>KRAS</i> G12D Inhibitor MRTX1133 in Pancreatic Cancer
   Becker, Jeffrey H., Metropulos, Anastasia E., Spaulding, Christina, Marinelarena, Alejandra M., Shields, Mario A., Principe, Daniel R., Pham, Thao D., Munshi, Hidayatullah G. · 2024 · Cancer Research
2. Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization
   Maruyama, Kohei, Shimizu, Yuki, Nomura, Yumi, Oh-hara, Tomoko, Takahashi, Yuki, Nagayama, Satoshi, Fujita, Naoya, Katayama, Ryohei · 2025 · npj Precision Oncology
3. High tumor mutation burden (TMB) in microsatellite stable (MSS) colorectal cancers: Diverse molecular associations point to variable pathophysiology
   Voutsadakis, Ioannis A. · 2023 · Cancer Treatment and Research Communications
4. Ready, Set, Go: Setting Off on the Mission to Target <i>KRAS</i> in Colorectal Cancer
   Pellatt, Andrew J., Bhamidipati, Deepak, Subbiah, Vivek · 2024 · JCO Oncology Practice
5. Exploring and bypassing resistance to targeted therapies in colorectal cancer
   Favier, Solène, Xiong, Wei, Chalabi-Dchar, Mounira, Chettab, Kamel, Piercey, Oliver, Wu, Ting, Fenouil, Tanguy, Albaret, Marie-Alexandra, Jordheim, Lars Petter, Diaz, Jean-Jacques et al. · 2025 · Biomedicine &amp; Pharmacotherapy
6. KRAS, a New Target for Precision Medicine in Colorectal Cancer?
   Boilève, Alice, Smolenschi, Cristina, Lambert, Aurélien, Boige, Valérie, Delaye, Matthieu, Camilleri, Géraldine M., Tarabay, Anthony, Valéry, Marine, Fuerea, Alina, Pudlarz, Thomas et al. · 2024 · Cancers
7. RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches
   Sütcüoğlu, Osman, Yıldırım, Hasan Çağrı, Almuradova, Elvina, Günenç, Damla, Yalçın, Şuayib · 2025 · Medicina
8. Differential Response and Resistance to KRAS-Targeted Therapy
   Liu, Zhaojin, Lenz, Heinz‐Josef, Yu, Jian, Zhang, Lin · 2025 · Molecular Carcinogenesis
9. EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance
   Abbas, Noura, Mourad, Mohamad, Smaily, Hiba, Al Mahmasani, Layal, Shamseddine, Ali · 2026 · International Journal of Molecular Sciences
10. Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials
    Li, Jian, Wang, Zhenghang, Huang, Jing, Ba, Yi, Cao, Baoshan, Luo, Suxia, Li, Wenhua, Bai, Chunmei, Song, Zhengbo, Xiong, Jianping et al. · 2026 · The Lancet Gastroenterology &amp; Hepatology
11. Characterization of KRASG12C inhibitor olomorasib single-agent and combination with activity in KRASG12C-mutant models
    Peng, Shengbin, Zhang, Youyan, Lin, Xi, Si, Chong, Van Horn, Robert Daniel, Dempsey, Jack A., Goetz, Eva, Evans, Robert J., Farber, Andrew, Vandekopple, Matthew J. et al. · 2026 · Nature Communications
12. Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies
    Kano, Yoshihito · 2026 · International Journal of Molecular Sciences
13. Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V
    Sagawa, Tamotsu, Hirakawa, Masahiro, Nagashima, Hiroyuki, Fujikawa, Koshi · 2026 · Journal of Gastrointestinal Cancer
14. Adaptive Feedback Signaling Through the FAK/SRC Pathway Promotes KRAS G12C Inhibitor Resistance
    Udagawa, Hibiki, Shibata, Yuji, Nilsson, Monique B., Nishii, Kazuya, Robichaux, Jacqulyne P., Galan-Cobo, Ana, He, Junqin, Poteete, Alissa, Qian, Yu, Molkentine, David et al. · 2026 · Journal of Thoracic Oncology